Quantcast

Latest Inovio Pharmaceuticals Inc. Stories

2014-05-27 04:21:46

BLUE BELL, Pa., May 27, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced that its 90%-owned subsidiary, VGX Animal Health, Inc. (VAH), has concluded an agreement for the sale of its animal health assets to Plumbline Life Sciences, Inc. (PLS) of Korea. The assets being transferred include an exclusive license with Inovio for animal applications of its growth hormone-releasing hormone (GHRH) technology and animal DNA vaccines plus a non-exclusive license...

2014-05-27 04:21:43

Protection Data Presented at the 17th Annual Meeting of the American Society of Gene & Cell Therapy BLUE BELL, Pa., May 27, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that its novel DNA-based therapeutic monoclonal antibody targeting Chikungunya virus (CHIKV) completely protected mice from a lethal CHIKV challenge. In this preclinical study, a prototype DNA plasmid construct encoding for a monoclonal antibody for CHIKV envelope protein was...

2014-05-23 04:20:51

BLUE BELL, Pa., May 23, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced that at the Company's Annual General Meeting held May 22, 2014, the Company's shareholders approved the proposal of a reverse split of the Company's common stock. The Company's Board of Directors subsequently approved the immediate implementation of a 1-for-4 reverse stock split of Inovio's common stock, where each 4 shares of issued and outstanding common stock and equivalents...

2014-05-21 04:21:27

BLUE BELL, Pa., May 21, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that Dr. Joseph Kim, President and CEO, will give a corporate presentation at the Jefferies 2014 Global Healthcare Conference taking place June 2-5 at the Grand Hyatt Hotel in New York City. Inovio PresentationMonday, June 2, 20148:00 AM ET A live webcast of Dr. Kim's presentation can be accessed at the following URL: http://wsw.com/webcast/jeff82/INO. An archived version of...

2014-05-13 04:22:33

BLUE BELL, Pa., May 13, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today it acquired worldwide rights (excluding China) for early preclinical therapies addressing Alzheimer's disease and multiple sclerosis based on the academic research of Dr. Bin Wang, a professor at Fudan University's Shanghai Medical College. Dr. Wang is a pioneer in the field of DNA therapies, having worked closely with Dr. David Weiner at the University of Pennsylvania. Dr. Wang was the...

2014-05-12 08:30:31

BLUE BELL, Pa., May 12, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today reported financial results for the quarter ended March 31, 2014. Total revenue was $2.4 million for the three months ended March 31, 2014, compared to $1.5 million for the same period in 2013. Total operating expenses were $12.4 million compared to $8.1 million. The loss from operations prior to other income (expenses) for the quarter ended March 31, 2014, was $10.0 million, or $0.05...

2014-05-05 04:22:00

BLUE BELL, Pa., May 5, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that it will host a conference call and live webcast to report its first quarter 2014 financial results on Monday, May 12, 2014, at 8:30 a.m. ET. Management will discuss first quarter earnings and expectations for the current and upcoming quarters. The audio presentation will be broadcast online at http://www.investorcalendar.com/IC/CEPage.asp?ID=172676. Investors can also access...

2014-04-01 04:20:52

Immunotherapy and Vaccine Leader Also Promotes Three Executives in Legal, Clinical and Investor Relations BLUE BELL, Pa., April 1, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced the appointment of E.J. Brandreth as Vice President of Quality. He will be responsible for all quality and compliance functions for a company that is moving forward with numerous late and early stage clinical trials and scaling up manufacturing and other operational areas to support...

2014-03-26 04:20:59

Biotech Judged First-in-Class for Cervical Pre-Cancer Immunotherapy (VGX-3100), Which Reports Phase II Results Mid-year 2014 BLUE BELL, Pa., March 26, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced that it was recognized with three industry awards at the World Vaccine Congress, which is being held this week in Washington, D.C. The Vaccine Industry Excellence (ViE) Awards recognize outstanding vaccine advancements and achievements of therapeutic...

2014-03-17 04:21:39

BLUE BELL, Pa., March 17, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today reported financial results for the fourth quarter and year ended December 31, 2013. Total revenue was $1.7 million and $13.5 million for the quarter and year ended December 31, 2013, as compared to $1.1 million and $4.1 million for the same periods in 2012. Total operating expenses for the quarter and year and ended December 31, 2013, were $9.7 million and $33.0 million as compared to...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.